

Cited in: EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.

Reviews

- Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case**
E. Roca, M. Pozzari, W. Vermi, V. Tovazzi, A. Baggi, V. Amoroso, D. Nonnis, S. Intagliata, A. Berruti (Italy) 12
- Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group**
D.B. Chapel (USA), A. Churg (Canada), E. Santoni-Rugiu (Denmark), T. Tsujimura, K. Hiroshima (Japan), A.N. Husain (USA) 69
- Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018)**
L. Wu (Canada), I. Dell'Anno (Italy), M. Lapidot (USA), Y. Sekido (Japan), M.-L. Chan, M. Kohno (Canada), V. Serre-Beinier, E. Felley-Bosco (Switzerland), M. de Perrot (Canada) 138
- Original Research Articles*
- Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer**
Y.-L. Wu, Q. Zhao, L. Deng, Y. Zhang, X.-J. Zhou, Y.-Y. Li, M. Yu, L. Zhou, B.-W. Zou, Y. Lu, Y.-M. Liu (China) 1
- Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial)**
T. Dotson, C. Bellinger, J. Su, K. Hansen, G.E. Parks, J.O. Cappellari, L. Craddock, H. Clark, C. Howard, W.J. Petty, B. Prakash, K. Watabe, M. Chan, J. Hovda, L.D. Miller, J. Ruiz (United States) 6
- Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer**
Y. Yu (China), Q. Ou, X. Wu (Canada), H. Bao (China), Y. Ding (Canada), Y.W. Shao (Canada, China), S. Lu (China) 19
- Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients**
J.C. Thompson, R. Fan, T. Black, G.H. Yu, S.L. Savitch, A. Chien, S.S. Yee, M. Sen, W.-T. Hwang, S.I. Katz, M. Feldman, A. Vachani, E.L. Carpenter (United States) 25
- High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients**
K.-H. Hsu, Y.-H. Huang, J.-S. Tseng, K.-C. Chen, W.-H. Ku, K.-Y. Su, J.J.W. Chen, H.-W. Chen, S.-L. Yu, T.-Y. Yang, G.-C. Chang (Taiwan) 37
- Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France**
C. Chouaid, L. Bensimon, E. Clay, A. Millier, L. Levy-Bachelot (France), M. Huang (USA), P. Levy (France) 44
- Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy**
A.D. Coutinho, M. Shah, O.E. Lunacsek, M. Eaddy, J.P. Willey (USA) 53
- Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion**
H. Sakai, M. Takeda, K. Sakai, Y. Nakamura, A. Ito, H. Hayashi, K. Tanaka, K. Nishio, K. Nakagawa (Japan) 59

(Contents continued overleaf)



Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer	
W. Haque, V. Verma, E.B. Butler, B.S. Teh, C.G. Rusthoven (USA)	76
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China	
X. Gu, Q. Zhang, Y.-B. Chu, Y.-Y. Zhao, Y.-J. Zhang, D. Kuo, B. Su, B. Wu (China)	84
Association of oral health with lung cancer risk in a low-income population of African Americans and European Americans in the Southeastern United States	
H.-S. Yoon, W. Wen, J. Long, W. Zheng, W.J. Blot, Q. Cai (USA)	90
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation	
J.B. Auliac, M. Pérol, D. Planchard, I. Monnet, M. Wislez, H. Doubre, F. Guisier, E. Pichon, L. Greillier, B. Mastroianni, C. Decroisette, R. Schott, S. Le Moulec, J. Arrondeau, A.B. Cortot, L. Gerinière, A. Renault, C. Daniel, L. Falchero, C. Chouaid (France)	96
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)	
B. Halmos (USA), E.-H. Tan, R.A. Soo (Singapore), J. Cadranet (France), M.K. Lee (South Korea), P. Foucher (France), T.-C. Hsia (Taiwan), M. Hochmair (Austria), F. Griesinger (Germany), T. Hida (Japan), E. Kim (USA), B. Melosky (Canada), A. Märten (Germany), E. Carcereny (Spain)	103
Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models	
K.H. Pyo, J.H. Kim, J.-M. Lee, S.E. Kim, J.S. Cho, S.M. Lim, B.C. Cho (South Korea)	112
Assessing the lung cancer comorbidity: An analysis of German claims data	
M. Murawski, J. Walter, L. Schwarzkopf (Germany)	122
Variable impact of prior cancer history on the survival of lung cancer patients	
A.F. Monsalve, J.R. Hoag, B.J. Resio, A.S. Chiu, L.B. Brown, F.C. Deterbeck, J.D. Blasberg, D.J. Boffa (USA)	130
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations	
H. Hasegawa, H. Yasuda, J. Hamamoto, K. Masuzawa, T. Tani, S. Nukaga, T. Hirano, K. Kobayashi, T. Manabe, H. Terai, S. Ikemura, I. Kawada, K. Naoki, K. Soejima (Japan)	146
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC	
G. Mazzaschi, F. Facchinetti, G. Missale, D. Canetti, D. Madeddu, A. Zecca, M. Veneziani, F. Gelsomino, M. Goldoni, S. Buti, P. Bordi, F. Aversa, A. Ardizzoni, F. Quaini, M. Tiseo (Italy)	153
<i>Short Communications</i>	
Outcomes of Stage III NSCLC with occult primary vs. known primary lesions	
P.B. Romesser, Y. Bardash, D. Buonocore, J.E. Chaft, J. Huang, D.R. Jones, A. Rimner, A.J. Wu (United States)	34
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma	
N. Kumar, D. Alrifai, K.K. Kolluri, E.K. Sage, Y. Ishii, N. Guppy, E. Borg, M. Falzon, M. Nankivell, A.G. Nicholson, S.M. Janes (United Kingdom)	164
<i>Case Reports</i>	
Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor	
S. Park, J. Han, J.-M. Sun (Republic of Korea)	66
<i>Correspondence</i>	
Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC	
R. Xu, J. Zhu (China)	167
Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC	
C.H. Suh, K.W. Kim (Republic of Korea), M. Nishino (USA)	168
Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations	
I. Tanaka, M. Morise, Y. Kodama, A. Matsui, N. Ozawa, S. Ozone, D. Goto, A. Miyazawa, T. Hase, N. Hashimoto, M. Sato, Y. Hasegawa (Japan)	169